SAIC Announces Third Quarter of Fiscal Year 2026 Results
Rhea-AI Summary
SAIC (NASDAQ: SAIC) reported third quarter fiscal 2026 results for the period ended October 31, 2025, with revenues of $1.87 billion, net income of $78 million, and adjusted EBITDA of $185 million (9.9% of revenues). The company reported net bookings of $2.2 billion for the quarter, a quarter book-to-bill of 1.2, and estimated backlog of $23.8 billion (≈$3.8 billion funded).
Management noted revenue headwinds including ~$16 million from the government shutdown and announced a preliminary acquisition (SilverEdge) for a $203 million purchase price. SAIC raised parts of its fiscal 2026 outlook: adjusted EBITDA ~ $695M and adjusted diluted EPS $9.80–$10.00. The Board declared a $0.37 per share quarterly dividend payable Jan 28, 2026.
Positive
- Net bookings of $2.2B in Q3
- Trailing twelve months book-to-bill ratio of 1.2
- Estimated backlog of $23.8B at quarter end
- Adjusted EBITDA guidance increased to approx. $695M
- Adjusted diluted EPS guidance raised to $9.80–$10.00
- Free cash flow in Q3 of $135M (vs $9M prior year)
Negative
- Revenues down 6% to $1.87B year-over-year
- Net income declined 26% to $78M in Q3
- Diluted EPS fell 21% to $1.69 in Q3
- Operating income down 20% to $128M year-over-year
Insights
Results show mixed execution: revenue contraction and EPS decline, but strong bookings, cash flow, and raised guidance on key metrics.
SAIC reported
The business mechanism is clear: government services revenue dipped due to contract ramp-downs and a ~
Key dependencies and risks include the pace of contract ramp-ups, realization of booked awards into revenue, and the effects of executive transition costs noted in the period. Monitor quarterly conversion of backlog to revenue, the company’s use of the MARPA facility reflected in working capital, and the integration of the SilverEdge acquisition (preliminary purchase price
- Revenues of
$1.87 billion - Net bookings of
$2.2 billion ; book-to-bill ratio and trailing twelve months book-to-bill ratio of 1.2 - Year-to-date net bookings of
$7.2 billion ; year-to-date book-to-bill ratio of 1.3 - Net income of
$78 million ; Adjusted EBITDA(1) of$185 million or9.9% of revenues - Diluted earnings per share of
$1.69 ; Adjusted diluted earnings per share(1) of$2.58 - Cash flows provided by operating activities of
$129 million ; Free cash flow(1) of$135 million - Company increases fiscal year 2026 guidance on certain key metrics
RESTON, Va., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corporation (NASDAQ: SAIC), a premier Fortune 500 technology integrator driving our nation's digital transformation across the defense, space, civilian, and intelligence markets, today announced results for the third quarter ended October 31, 2025.
"Our third quarter results reflect a
Third Quarter of Fiscal Year 2026: Summary Operating Results
| Three Months Ended | ||||||||||
| October 31, 2025 | Percent change | November 1, 2024 | ||||||||
| (dollars in millions, except per share amounts) | ||||||||||
| Revenues | $ | 1,866 | (6 | )% | $ | 1,976 | ||||
| Operating income | 128 | (20 | )% | 160 | ||||||
| Operating income as a percentage of revenues | 6.9 | % | -120bps | 8.1 | % | |||||
| Adjusted operating income(1) | 183 | (6 | )% | 195 | ||||||
| Adjusted operating income as a percentage of revenues | 9.8 | % | -10bps | 9.9 | % | |||||
| Net income | 78 | (26 | )% | 106 | ||||||
| EBITDA(1) | 168 | (15 | )% | 197 | ||||||
| EBITDA as a percentage of revenues | 9.0 | % | -100bps | 10.0 | % | |||||
| Adjusted EBITDA(1) | 185 | (6 | )% | 197 | ||||||
| Adjusted EBITDA as a percentage of revenues | 9.9 | % | -10bps | 10.0 | % | |||||
| Diluted earnings per share | $ | 1.69 | (21 | )% | $ | 2.13 | ||||
| Adjusted diluted earnings per share(1) | $ | 2.58 | (1 | )% | $ | 2.61 | ||||
| Net cash provided by operating activities | $ | 129 | (10 | )% | $ | 143 | ||||
| Free cash flow(1) | $ | 135 | 1,400 | % | $ | 9 | ||||
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Third Quarter Summary Results
Revenues for the quarter decreased
Operating income as a percentage of revenues for the quarter decreased compared to the same period in the prior year primarily due to executive transition costs, net of recoveries, and the favorable resolution of the Assault Amphibious Vehicle ("AAV") contract termination in the prior year (
Adjusted EBITDA(1) as a percentage of revenues for the quarter decreased to
Diluted earnings per share for the quarter was
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Cash Generation and Capital Deployment
Cash flows provided by operating activities for the third quarter decreased
During the quarter, SAIC deployed
Quarterly Dividend Declared
Subsequent to quarter end, on December 2, 2025, the Company's Board of Directors declared a cash dividend of
Backlog and Contract Awards
Net bookings for the quarter and year were approximately
Notable New and Recompete Awards:
U.S Air Force: During the quarter, SAIC was awarded the
U.S. Army: During the quarter, SAIC was awarded a
U.S. Navy: During the quarter, SAIC was awarded a
Naval Undersea Warfare Center: SAIC was awarded a
U.S. Space and Intelligence Community: During the quarter, SAIC was awarded approximately
Other Notable News:
On October 15, 2025, SAIC acquired SilverEdge Government Solutions ("SilverEdge"), an innovative provider of mission-driven technology solutions and products, for a preliminary purchase price of
Fiscal Year 2026 Guidance
The table below summarizes fiscal year 2026 guidance and represents the Company's views as of December 4, 2025.
| CURRENT | PRIOR | |
| Fiscal Year | Fiscal Year | |
| 2026 Guidance | 2026 Guidance | |
| Revenue | ||
| Adjusted EBITDA(1) | Approx. | |
| Adjusted EBITDA Margin %(1) | Approx. | |
| Adjusted Diluted EPS(1) | ||
| Free Cash Flow(1) | > | > |
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Webcast Information
SAIC management will discuss operations and financial results in an earnings conference call beginning at 10:00 a.m. Eastern time on December 4, 2025. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the SAIC website (investors.saic.com). We will be providing webcast access only – “dial-in” access is no longer available. Additionally, a supplemental presentation will be available to the public through links to the Investor Relations section of the SAIC website. After the call concludes, an on-demand audio replay of the webcast can be accessed on the Investor Relations website.
About SAIC
SAIC® is a premier Fortune 500 mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.
We are approximately 24,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately
Contacts
Investor Relations: Joe DeNardi, joseph.w.denardi@saic.com
Media: Kara Ross, kara.g.ross@saic.com
GAAP to Non-GAAP Guidance Reconciliation
The Company does not provide a reconciliation of forward-looking adjusted diluted EPS to GAAP diluted EPS, adjusted EBITDA margin to GAAP net income or free cash flow to GAAP net cash flows from operating activities due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate net income and cash flows from operating activities may vary significantly based on actual events, the Company is not able to forecast GAAP diluted EPS, GAAP net income or GAAP net cash flows from operating activities with reasonable certainty. The variability of the above charges may have an unpredictable and potentially significant impact on our future GAAP financial results.
Forward-Looking Statements
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at www.saic.com or on the SEC’s website at www.sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.
Schedule 1:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| October 31, 2025 | November 1, 2024 | October 31, 2025 | November 1, 2024 | ||||||||||||
| (in millions, except per share amounts) | |||||||||||||||
| Revenues | $ | 1,866 | $ | 1,976 | $ | 5,512 | $ | 5,641 | |||||||
| Cost of revenues | 1,639 | 1,739 | 4,861 | 4,981 | |||||||||||
| Selling, general and administrative expenses | 101 | 83 | 265 | 245 | |||||||||||
| Other operating (income) expense | (2 | ) | (6 | ) | (2 | ) | (10 | ) | |||||||
| Operating income | 128 | 160 | 388 | 425 | |||||||||||
| Interest expense, net | 33 | 32 | 94 | 97 | |||||||||||
| Other (income) expense, net | 1 | 2 | 6 | 7 | |||||||||||
| Income before income taxes | 94 | 126 | 288 | 321 | |||||||||||
| Income tax (expense) benefit | (16 | ) | (20 | ) | (15 | ) | (57 | ) | |||||||
| Net income | $ | 78 | $ | 106 | $ | 273 | $ | 264 | |||||||
| Weighted-average number of shares outstanding: | |||||||||||||||
| Basic | 45.9 | 49.4 | 46.7 | 50.6 | |||||||||||
| Diluted | 46.1 | 49.8 | 46.9 | 51.1 | |||||||||||
| Earnings per share: | |||||||||||||||
| Basic | $ | 1.70 | $ | 2.15 | $ | 5.85 | $ | 5.22 | |||||||
| Diluted | $ | 1.69 | $ | 2.13 | $ | 5.82 | $ | 5.17 | |||||||
Schedule 2:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||||
| October 31, 2025 | January 31, 2025 | ||||||
| (in millions) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 45 | $ | 56 | |||
| Receivables, net | 1,045 | 1,000 | |||||
| Prepaid expenses | 145 | 78 | |||||
| Other current assets | 22 | 20 | |||||
| Total current assets | 1,257 | 1,154 | |||||
| Goodwill | 2,960 | 2,851 | |||||
| Intangible assets, net | 779 | 779 | |||||
| Property, plant, and equipment, net | 108 | 104 | |||||
| Operating lease right of use assets | 162 | 164 | |||||
| Other assets | 157 | 194 | |||||
| Total assets | $ | 5,423 | $ | 5,246 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 627 | $ | 631 | |||
| Accrued payroll and employee benefits | 308 | 339 | |||||
| Other accrued liabilities | 103 | 113 | |||||
| Debt, current portion | 12 | 313 | |||||
| Total current liabilities | 1,050 | 1,396 | |||||
| Debt, net of current portion | 2,475 | 1,907 | |||||
| Operating lease liabilities | 159 | 173 | |||||
| Deferred income taxes | 124 | 24 | |||||
| Other long-term liabilities | 103 | 169 | |||||
| Equity: | |||||||
| Total stockholders' equity | 1,512 | 1,577 | |||||
| Total liabilities and stockholders' equity | $ | 5,423 | $ | 5,246 | |||
Schedule 3:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| October 31, 2025 | November 1, 2024 | October 31, 2025 | November 1, 2024 | ||||||||||||
| (in millions) | |||||||||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income | $ | 78 | $ | 106 | $ | 273 | $ | 264 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 38 | 35 | 109 | 104 | |||||||||||
| Stock-based compensation expense | 26 | 13 | 51 | 38 | |||||||||||
| Deferred income taxes | (8 | ) | (7 | ) | 101 | (15 | ) | ||||||||
| Gain on sale of equity method investments | — | (5 | ) | — | (5 | ) | |||||||||
| Other | (4 | ) | (1 | ) | (4 | ) | (4 | ) | |||||||
| Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of acquisitions: | |||||||||||||||
| Receivables | (80 | ) | (76 | ) | (31 | ) | (108 | ) | |||||||
| Prepaid expenses and other current assets | 39 | 17 | (68 | ) | 31 | ||||||||||
| Accounts payable and other accrued liabilities | 62 | 80 | (22 | ) | 119 | ||||||||||
| Accrued payroll and employee benefits | (33 | ) | (27 | ) | (36 | ) | (59 | ) | |||||||
| Operating lease assets and liabilities, net | (1 | ) | (2 | ) | (5 | ) | (7 | ) | |||||||
| Other assets and other long-term liabilities, net | 12 | 10 | (17 | ) | 21 | ||||||||||
| Net cash provided by operating activities | 129 | 143 | 351 | 379 | |||||||||||
| Cash flows from investing activities: | |||||||||||||||
| Cash paid for acquisitions, net of cash acquired | (203 | ) | — | (203 | ) | — | |||||||||
| Expenditures for property, plant, and equipment | (9 | ) | (9 | ) | (24 | ) | (21 | ) | |||||||
| Purchases of marketable securities | (1 | ) | (3 | ) | (5 | ) | (11 | ) | |||||||
| Sales of marketable securities | 1 | 4 | 5 | 10 | |||||||||||
| Proceeds from sale of equity method investments | — | 10 | — | 10 | |||||||||||
| Contributions to investments | (3 | ) | (1 | ) | (10 | ) | (3 | ) | |||||||
| Net cash (used in) provided by investing activities | (215 | ) | 1 | (237 | ) | (15 | ) | ||||||||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from borrowings | 1,438 | 441 | 2,745 | 1,114 | |||||||||||
| Principal payments on borrowings | (1,238 | ) | (450 | ) | (2,473 | ) | (1,056 | ) | |||||||
| Stock repurchased and retired or withheld for taxes on equity awards | (95 | ) | (121 | ) | (347 | ) | (425 | ) | |||||||
| Dividend payments to stockholders | (17 | ) | (18 | ) | (53 | ) | (57 | ) | |||||||
| Issuances of stock | 4 | 5 | 16 | 14 | |||||||||||
| Debt issuance costs | (9 | ) | — | (9 | ) | — | |||||||||
| Other | — | (3 | ) | (4 | ) | (3 | ) | ||||||||
| Net cash provided by (used in) financing activities | 83 | (146 | ) | (125 | ) | (413 | ) | ||||||||
| Net decrease in cash, cash equivalents and restricted cash | (3 | ) | (2 | ) | (11 | ) | (49 | ) | |||||||
| Cash, cash equivalents and restricted cash at beginning of period | 56 | 56 | 64 | 103 | |||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 53 | $ | 54 | $ | 53 | $ | 54 | |||||||
Schedule 4:
| SCIENCE APPLICATIONS INTERNATIONAL CORPORATION SEGMENT OPERATING RESULTS (Unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| October 31, 2025 | November 1, 2024 | October 31, 2025 | November 1, 2024 | ||||||||||||
| (dollars in millions) | |||||||||||||||
| Revenues | |||||||||||||||
| Defense and Intelligence | $ | 1,439 | $ | 1,515 | $ | 4,246 | $ | 4,366 | |||||||
| Civilian | 427 | 461 | 1,266 | 1,275 | |||||||||||
| Total revenues | $ | 1,866 | $ | 1,976 | $ | 5,512 | $ | 5,641 | |||||||
| Adjusted operating income (loss) | |||||||||||||||
| Defense and Intelligence | $ | 118 | $ | 148 | $ | 357 | $ | 396 | |||||||
| Civilian | 62 | 49 | 168 | 141 | |||||||||||
| Corporate | 3 | (2 | ) | (2 | ) | (8 | ) | ||||||||
| Total adjusted operating income | $ | 183 | $ | 195 | $ | 523 | $ | 529 | |||||||
| Adjusted operating margin | |||||||||||||||
| Defense and Intelligence | 8.2 | % | 9.8 | % | 8.4 | % | 9.1 | % | |||||||
| Civilian | 14.5 | % | 10.6 | % | 13.3 | % | 11.1 | % | |||||||
| Total adjusted operating margin | 9.8 | % | 9.9 | % | 9.5 | % | 9.4 | % | |||||||
Third Quarter Defense and Intelligence Results
Revenues for the quarter decreased
Adjusted operating income as a percentage of revenues decreased compared to the same period in the prior year primarily due to timing and volume mix in our contract portfolio and the favorable resolution of the AAV contract termination in the prior year (
Third Quarter Civilian Results
Revenues for the quarter decreased
Adjusted operating income as a percentage of revenues increased from the comparable prior year period primarily due to improved profitability across our contract portfolio.
Third Quarter Corporate Results
Adjusted operating income was
Schedule 5:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
BACKLOG
(Unaudited)
The estimated value of our total backlog as of the dates presented was:
| October 31, 2025 | January 31, 2025 | |||||||||||||||||
| Defense and Intelligence | Civilian | Total SAIC | Defense and Intelligence | Civilian | Total SAIC | |||||||||||||
| (in millions) | ||||||||||||||||||
| Funded backlog | $ | 2,696 | $ | 1,127 | $ | 3,823 | $ | 2,599 | $ | 845 | $ | 3,444 | ||||||
| Negotiated unfunded backlog | 16,753 | 3,212 | 19,965 | 15,341 | 3,072 | 18,413 | ||||||||||||
| Total backlog | $ | 19,449 | $ | 4,339 | $ | 23,788 | $ | 17,940 | $ | 3,917 | $ | 21,857 | ||||||
Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts and task orders as work is performed and excludes contract awards which have been protested by competitors until the protest is resolved in our favor. SAIC segregates backlog into two categories, funded backlog and negotiated unfunded backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government agencies represents the estimated value of contracts which may cover multiple future years under which SAIC is obligated to perform, less revenues previously recognized on these contracts. Negotiated unfunded backlog represents the estimated future revenues to be earned from negotiated contracts for which funding has not been appropriated or authorized, and unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under indefinite delivery, indefinite quantity (IDIQ), U.S. General Services Administration (GSA) schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.
Schedule 6:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
This schedule describes the consolidated non-GAAP financial measures included in this earnings release. While we believe that these non-GAAP financial measures may be useful in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.
Adjusted Operating Income
| Three Months Ended | Nine Months Ended | ||||||||||||||
| October 31, 2025 | November 1, 2024 | October 31, 2025 | November 1, 2024 | ||||||||||||
| (dollars in millions) | |||||||||||||||
| Revenues | $ | 1,866 | $ | 1,976 | $ | 5,512 | $ | 5,641 | |||||||
| Operating income | $ | 128 | $ | 160 | $ | 388 | $ | 425 | |||||||
| Operating income as a percentage of revenues | 6.9 | % | 8.1 | % | 7.0 | % | 7.5 | % | |||||||
| Depreciation of property, plant and equipment | 9 | 6 | 22 | 17 | |||||||||||
| Amortization of intangible assets | 29 | 29 | 87 | 87 | |||||||||||
| Acquisition, integration, restructuring and impairment costs | 1 | — | 5 | 2 | |||||||||||
| Recovery of acquisition, integration, restructuring and impairment costs | — | — | (2 | ) | (2 | ) | |||||||||
| Costs related to the settlement of federal tax audits | — | — | 7 | — | |||||||||||
| Executive transition costs, net of recoveries | 16 | — | 16 | — | |||||||||||
| Adjusted operating income(1) | $ | 183 | $ | 195 | $ | 523 | $ | 529 | |||||||
| Adjusted operating income as a percentage of revenues | 9.8 | % | 9.9 | % | 9.5 | % | 9.4 | % | |||||||
Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, the reorganization, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Depreciation of property, plant, and equipment relates to property, plant, and equipment specifically identifiable for each segment. Adjusted operating income also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. Executive transition costs, net of recoveries, represent costs associated with the immediate departure of our CEO and other executives, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. We believe that this performance measure provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
EBITDA and Adjusted EBITDA
| Three Months Ended | Nine Months Ended | ||||||||||||||
| October 31, 2025 | November 1, 2024 | October 31, 2025 | November 1, 2024 | ||||||||||||
| (dollars in millions) | |||||||||||||||
| Revenues | $ | 1,866 | $ | 1,976 | $ | 5,512 | $ | 5,641 | |||||||
| Net income | $ | 78 | $ | 106 | $ | 273 | $ | 264 | |||||||
| Interest expense, net and loss on sale of receivables | 36 | 36 | 104 | 108 | |||||||||||
| Income tax expense (benefit) | 16 | 20 | 15 | 57 | |||||||||||
| Depreciation and amortization | 38 | 35 | 109 | 104 | |||||||||||
| EBITDA(1) | 168 | 197 | 501 | 533 | |||||||||||
| EBITDA as a percentage of revenues | 9.0 | % | 10.0 | % | 9.1 | % | 9.4 | % | |||||||
| Acquisition, integration, restructuring and impairment costs | 1 | — | 5 | 2 | |||||||||||
| Recovery of acquisition, integration, restructuring and impairment costs | — | — | (2 | ) | (2 | ) | |||||||||
| Costs related to the settlement of federal tax audits | — | — | 7 | — | |||||||||||
| Executive transition costs, net of recoveries | 16 | — | 16 | — | |||||||||||
| Adjusted EBITDA(1) | $ | 185 | $ | 197 | $ | 527 | $ | 533 | |||||||
| Adjusted EBITDA as a percentage of revenues | 9.9 | % | 10.0 | % | 9.6 | % | 9.4 | % | |||||||
EBITDA is a performance measure that is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition, integration, restructuring and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, the reorganization, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. Executive transition costs, net of recoveries, represent costs associated with the immediate departure of our CEO and other executives, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Diluted Earnings Per Share
| Three Months Ended October 31, 2025 | |||||||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||
| As Reported | Acquisition, integration, restructuring and impairment costs | Amortization of intangible assets | Executive transition costs, net of recoveries | Non-GAAP results(1) | |||||||||||||||
| Income before income taxes | $ | 94 | $ | 1 | $ | 29 | $ | 16 | $ | 140 | |||||||||
| Income tax (expense) benefit | (16 | ) | — | (5 | ) | — | (21 | ) | |||||||||||
| Net income | $ | 78 | $ | 1 | $ | 24 | $ | 16 | $ | 119 | |||||||||
| Diluted EPS | $ | 1.69 | $ | 0.02 | $ | 0.52 | $ | 0.35 | $ | 2.58 | |||||||||
| Three Months Ended November 1, 2024 | |||||||||||
| (in millions, except per share amounts) | |||||||||||
| As Reported | Amortization of intangible assets | Non-GAAP results(1) | |||||||||
| Income before income taxes | $ | 126 | $ | 29 | $ | 155 | |||||
| Income tax (expense) benefit | (20 | ) | (5 | ) | (25 | ) | |||||
| Net income | $ | 106 | $ | 24 | $ | 130 | |||||
| Diluted EPS | $ | 2.13 | $ | 0.48 | $ | 2.61 | |||||
Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, the reorganization, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Executive transition costs, net of recoveries, represent costs associated with the immediate departure of our CEO and other executives, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. We believe that this performance measure provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Diluted Earnings Per Share
| Nine Months Ended October 31, 2025 | |||||||||||||||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||||||||||
| As Reported | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Amortization of intangible assets | Costs related to the settlement of federal tax audits | Executive transition costs, net of recoveries | Non-GAAP results(1) | |||||||||||||||||||||
| Income before income taxes | $ | 288 | $ | 5 | $ | (2 | ) | $ | 87 | $ | 7 | $ | 16 | $ | 401 | ||||||||||||
| Income tax (expense) benefit | (15 | ) | — | — | (5 | ) | — | — | (20 | ) | |||||||||||||||||
| Net income | $ | 273 | $ | 5 | $ | (2 | ) | $ | 82 | $ | 7 | $ | 16 | $ | 381 | ||||||||||||
| Diluted EPS | $ | 5.82 | $ | 0.10 | $ | (0.04 | ) | $ | 1.75 | $ | 0.15 | $ | 0.34 | $ | 8.12 | ||||||||||||
| Nine Months Ended November 1, 2024 | |||||||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||||
| As Reported | Acquisition, integration, restructuring and impairment costs | Recovery of acquisition, integration, restructuring and impairment costs | Amortization of intangible assets | Non-GAAP results(1) | |||||||||||||||
| Income before income taxes | $ | 321 | $ | 2 | $ | (2 | ) | $ | 87 | $ | 408 | ||||||||
| Income tax (expense) benefit | (57 | ) | — | — | (16 | ) | (73 | ) | |||||||||||
| Net income | $ | 264 | $ | 2 | $ | (2 | ) | $ | 71 | $ | 335 | ||||||||
| Diluted EPS | $ | 5.17 | $ | 0.04 | $ | (0.04 | ) | $ | 1.39 | $ | 6.56 | ||||||||
Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, the reorganization, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. Executive transition costs, net of recoveries, represent costs associated with the immediate departure of our CEO and other executives, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. We believe that this performance measure provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.
(1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Free Cash Flow
| Three Months Ended | Nine Months Ended | ||||||||||||||
| October 31, 2025 | November 1, 2024 | October 31, 2025 | November 1, 2024 | ||||||||||||
| (in millions) | |||||||||||||||
| Net cash provided by operating activities | $ | 129 | $ | 143 | $ | 351 | $ | 379 | |||||||
| Expenditures for property, plant, and equipment | (9 | ) | (9 | ) | (24 | ) | (21 | ) | |||||||
| Cash used from (provided by) MARPA Facility | 15 | (125 | ) | (86 | ) | (95 | ) | ||||||||
| Free cash flow(1) | $ | 135 | $ | 9 | $ | 241 | $ | 263 | |||||||
| FY26 Guidance | |
| (in millions) | |
| Net cash provided by operating activities | > |
| Expenditures for property, plant, and equipment | Approximately |
| Free cash flow(1) | > |
Free cash flow is calculated by taking cash flows provided by operating activities less expenditures for property, plant, and equipment and less cash flows from our Master Accounts Receivable Purchasing Agreement (MARPA Facility) for the sale of certain designated eligible U.S. government receivables. Under the MARPA Facility, the Company can sell eligible receivables up to a maximum amount of
(1)Non-GAAP measure, see above for definition.